Send us Feedback

Medicines Company (MDCO)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW
QUOTE AND NEWS
Medicines (MDCO) Trading Near $35.79 Support Level
Market Intelligence Center  May 14  Comment 
Medicines Company (NASDAQ: MDCO) closed Monday's trading session at $36.64. In the past year, the stock has hit a 52-week low of $20.04 and 52-week high of $37.33. Medicines (MDCO) stock has been showing support around $35.79 and resistance in the...
Stocks Hitting 52-Week Highs
Benzinga  May 10  Comment 
The Medicines Company (NASDAQ: MDCO) shares jumped 2.35% to create a new 52-week high of $36.60. Medicines has posted four consecutive quarters of EPS gains, with Q1 earnings rising 63% Wet Seal Inc (NASDAQ: WTSL) shares gained 02.15% to touch...
(MDCO) The Medicines Company Earnings Increase
Stock Blog Hub  Apr 29  Comment 
The Medicines Company (MDCO) reported first quarter earnings of 24 cents per share, compared with the year-ago earnings of 14 cents per share. Including one-time items, the company reported a loss of 21 cents per share compared to the year-ago...
Medicines Co (MDCO) Posts Q1 adj.-EPS of 31c
StreetInsider.com  Apr 24  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Medicines+Co+%28MDCO%29+Posts+Q1+adj.-EPS+of+31c/8273908.html for the full story.
Medicines (MDCO) Showing Bullish Technicals But Could Break Through $33.88 Resistance
Market Intelligence Center  Apr 8  Comment 
Medicines Company (NASDAQ: MDCO) closed Friday's trading session at $32.43. In the past year, the stock has hit a 52-week low of $19.37 and 52-week high of $35.19. Medicines (MDCO) stock has been showing support around $30.72 and resistance in the...
Medicines (MDCO) Trading Near $34.09 Resistance Level
Market Intelligence Center  Apr 2  Comment 
Medicines Company (NASDAQ: MDCO) closed Monday's trading session at $33.01. In the past year, the stock has hit a 52-week low of $19.37 and 52-week high of $35.19. Medicines (MDCO) stock has been showing support around $32.21 and resistance in the...
UPDATE: Credit Suisse Initiates The Medicines Company at Outperform on Pipeline Catalysts
Benzinga  Mar 15  Comment 
Credit Suisse initiated The Medicines Company (NASDAQ: MDCO) with an Outperform rating and a $38.00 price target. Credit Suisse analyst Jason Kantor noted, "MDCO should gain operational synergy with four potential new product launches in 2014....
Medicines Co.'s blood thinner finally reaps positive results in third PhIII
FierceBiotech  Mar 11  Comment 
If at first you don't succeed in Phase III, try, try again. Only enroll lots more patients and improve the trial design. That was The Medicines Company's ($MDCO) strategy when it opted to pay for a third pivotal study of the blood thinner...
Medicines (MDCO) Showing Bullish Technicals But Could Break Through $34.65 Resistance
Market Intelligence Center  Feb 21  Comment 
Medicines Company (NASDAQ: MDCO) closed Wednesday's trading session at $32.57. In the past year, the stock has hit a 52-week low of $19.37 and 52-week high of $33.25. Medicines (MDCO) stock has been showing support around $29.77 and resistance in...
Medicines Co (MDCO) Tops Q4 EPS by 10c
StreetInsider.com  Feb 20  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Medicines+Co+%28MDCO%29+Tops+Q4+EPS+by+10c/8114553.html for the full story.




RELATED WIKI ARTICLES

Related Articles

more ▼WIKI ANALYSIS
 

Based in Parsippany, NJ, The Medicines Company (MDCO) is engaged in acquiring, developing, and marketing specialty pharmaceutical primarily for cardiovascular indications. Its leading product, Angiomax (bivalirudin), which was acquired from Biogen Idec, Inc. in 1996, is used as an anticoagulant in patients undergoing coronary angioplasty. The company's other late-stage products include Clevidipine and Cangrelor, both acquired from AstraZeneca several years ago. Clevidipine is an intravenous drug (calcium channel blocker) intended for the short-term control of blood pressure in patients undergoing cardiac surgery. Cangrelor is an intravenous anticoagulant, having potential uses in coronary angioplasty and cardiac surgery. The company sells its products through its own sales force and distributors. In 2006, sales of Angiomax helped generate $214.0 million revenue.




References

Retrieved from "http://www.wikinvest.com/stock/Medicines_Company_(MDCO)"
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki